// App-Quantinova.ai

P552 : Early use of vedolizumab vs. infliximab in biologic-naive patients with ulcerative colitis: A real-world analysis of healthcare utilisation

Researchers

Presenter

  • H Patel

Principal Investigators

  • J M Khalid

  • S Shah

  • R Shah

  • A Berger

Medical Centers

  • Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK

  • Evidera, Real World Evidence, Waltham, MA, USA

  • Evidera, Real World Evidence, London, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

  • Infliximab

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved